Patent ID: 8158661

Claim:
A method of treating a GSK-3 mediated disease or condition selected from the group consisting of amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, corticobasal degeneration, Huntington's disease, frontotemporal dementia, guam parkinsonism-dementia complex, Pick's disease, or AIDS associated dementia, in a patient in need thereof, the method comprising administering to said patient a compound according to formula (I) or a pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant, or vehicle, and a compound according to formula (I) or a pharmaceutically acceptable salt or prodrug thereof; wherein: R 1 is a group selected from the group consisting of: R a , R b , R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, —COR 7 , —C(O)OR 7 , —C(O)NR 7 R 8 , —C═NR 7 , —CN, —OR 7 , —OC(O)R 7 , —S(O) t —R 7 , —NR 7 R 8 , —NR 7 C(O)R 8 , —NO 2 , —N═CR 7 R 8 or halogen; t is 0, 1, 2 or 3; and R 7 and R 8 are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted substituted or unsubstituted aryloxy, or halogen.